Compare KMX & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMX | PTCT |
|---|---|---|
| Founded | 1993 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.5B |
| IPO Year | 2002 | 2006 |
| Metric | KMX | PTCT |
|---|---|---|
| Price | $56.07 | $78.02 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 16 | 17 |
| Target Price | $37.18 | ★ $80.65 |
| AVG Volume (30 Days) | ★ 3.5M | 2.2M |
| Earning Date | 04-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 264.48 |
| EPS | ★ 1.31 | N/A |
| Revenue | ★ $25,881,131,000.00 | $264,734,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.82 | $17.70 |
| P/E Ratio | $42.68 | ★ N/A |
| Revenue Growth | N/A | ★ 36.19 |
| 52 Week Low | $30.40 | $43.18 |
| 52 Week High | $63.74 | $90.87 |
| Indicator | KMX | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 61.38 | 45.33 |
| Support Level | $39.39 | $73.41 |
| Resistance Level | N/A | $79.67 |
| Average True Range (ATR) | 2.08 | 3.37 |
| MACD | 0.22 | -1.28 |
| Stochastic Oscillator | 56.95 | 10.58 |
CarMax sells, finances, and services used and new cars through a chain of over 250 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales were 83% of fiscal 2025 revenue and wholesale about 17%, with the remaining portion composed of extended service plans and repair. In fiscal 2025, the company retailed and wholesaled 789,050 and 544,312 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the US but still estimates that it had only about 3.7% US market share of vehicles 0-10 years old in calendar 2024. It seeks over 5% share. CarMax is based in Richmond, Virginia.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.